Your session is about to expire
← Back to Search
Radiation Therapy
Radiation therapy for COVID-19 (VENTED Trial)
Phase 2
Recruiting
Led By Arnab Chakravarti
Research Sponsored by Ohio State University Comprehensive Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Laboratory Diagnosis of COVID-19 based within 14 days of enrollment.
CT or radiographic findings typical of COVID-19 pneumonia within 5 days of enrollment
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 18 months post radiation delivery
Awards & highlights
VENTED Trial Summary
This trial is testing whether low doses of radiation can help to treat people with pneumonia caused by COVID-19.
Eligible Conditions
- COVID-19
- Coronavirus
VENTED Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowVENTED Trial Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 18 months post radiation delivery
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 18 months post radiation delivery
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Mortality rate of subjects treated with whole lung low-dose radiation
Secondary outcome measures
Change in number of Intensive care unit days
Change in number of days using supplemental oxygen
Change in oxygenation index/oxygen saturation index for 14 days post treatment or until extubated
+6 moreSide effects data
From 2013 Phase 3 trial • 397 Patients • NCT0000405478%
Menopausal symptoms
60%
Urinary frequency
52%
Impotence
47%
Late RT Toxicity: Bladder: NOS
39%
Diarrhea NOS
27%
Late RT Toxicity: Bowel: NOS
26%
Fatigue
26%
Late RT Toxicity: Other GU: NOS
21%
Proctitis NOS
21%
Dysuria
14%
Libido decreased
14%
Dermatitis radiation NOS
12%
Late RT Toxicity: Other GI: NOS
12%
Late RT Toxicity: Other: NOS
12%
Hemoglobin decreased
12%
Alanine aminotransferase increased
9%
Gynaecomastia
8%
Urinary retention
7%
Pain-other
7%
Aspartate aminotransferase increased
6%
Rectal bleeding
6%
Constipation
6%
Leukopenia NOS
4%
Edema NOS
4%
Hematuria present
4%
Renal/GU-Other
3%
Arthralgia
3%
Blood creatinine increased
3%
Dyspnea NOS
3%
Dermatitis exfoliative NOS
2%
Nausea
2%
Hyperglycemia NOS
2%
Depression NEC
2%
Lymphopenia
2%
Myalgia
2%
Peripheral sensory neuropathy
1%
Stomatitis
1%
Blood albumin decreased
1%
Platelet count decreased
1%
Weight decreased
1%
Anorexia
1%
Hypocalcemia
1%
Hyponatremia
1%
Hematologic-Other
1%
Neutropenia
1%
Alopecia
100%
80%
60%
40%
20%
0%
Study treatment Arm
Hormones and RT
Hormones and RT Plus Chemotherapy
VENTED Trial Design
1Treatment groups
Experimental Treatment
Group I: Radiation ArmExperimental Treatment1 Intervention
Each subject will receive a dose of whole lung radiation. A second optional dose of 80 cGy may be delivered if no improvement after 3-10 days.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Radiation therapy
2013
Completed Phase 3
~2850
Find a Location
Who is running the clinical trial?
Ohio State University Comprehensive Cancer CenterLead Sponsor
319 Previous Clinical Trials
290,124 Total Patients Enrolled
1 Trials studying COVID-19
37 Patients Enrolled for COVID-19
Arnab ChakravartiPrincipal Investigator - James Cancer Hospital, Department of Radiation Oncology
Ohio State University Comprehensive Cancer Center
1 Previous Clinical Trials
158 Total Patients Enrolled
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
Share this study with friends
Copy Link
Messenger